Stem Cell Manufacturing Market Report 2026

The stem cell manufacturing market size has grown rapidly in recent years. It will grow from $19.17 billion in 2025 to $21.45 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to clinical trial growth, stem cell therapy approvals, bioprocessing investments, regulatory framework development, contract manufacturing expansion.

The stem cell manufacturing market size is expected to see rapid growth in the next few years. It will grow to $33.55 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to commercial-scale therapy production, cost reduction technologies, decentralized manufacturing models, advanced cell expansion techniques, regulatory harmonization. Major trends in the forecast period include closed-system bioreactors, scalable manufacturing platforms, automation of cell expansion, quality-by-design processes, cryopreservation optimization.

The growing geriatric population is expected to drive the growth of the stem cell manufacturing market in the coming years. The geriatric population includes adults aged 65 and older, who are more susceptible to various diseases due to reduced immunity and aging. Aging increases the risk of chronic diseases, and stem cell manufacturing offers potential solutions to address these health challenges. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, reported that the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. The share of this age group in the overall population is also expected to grow from 17% to 23% during the same period. Therefore, the rising geriatric population is fueling growth in the stem cell manufacturing market.

Key companies in the stem cell manufacturing market are focusing on developing innovative products, such as GMP-grade proteins, to maintain a competitive advantage. GMP-grade protein refers to protein powders and other protein products that meet strict quality and safety standards. For instance, in November 2023, ACROBiosystems Inc., a US-based provider of recombinant proteins and critical reagents, launched GMP-grade DLL4 protein. This recombinant, soluble form of Delta-like Ligand 4 (DLL4) is a crucial signaling molecule in stem cell development and differentiation. The availability of GMP-grade DLL4 represents a major step forward in developing stem cell-based therapies, offering a high-quality, consistent, and scalable source of this essential protein. DLL4 is known to promote the self-renewal and expansion of hematopoietic stem cells (HSCs), which give rise to all blood cells and can be used to supplement in vitro stem cell cultures, thereby enhancing HSC growth and differentiation.

In April 2025, NeuroScientific Biopharmaceuticals Ltd, an Australia-based biotechnology company, acquired Isopogen WA Ltd. for an undisclosed amount. Through this acquisition, NeuroScientific aims to expand its stem cell portfolio, strengthen research and development capabilities, accelerate the creation of novel cell-based therapies, and enhance its position in the regenerative medicine market. Isopogen WA Ltd., based in Australia, provides advanced stem cell technologies and solutions for preclinical and translational research.

Major companies operating in the stem cell manufacturing market are Thermo Fisher Scientific Inc., Merck Millipore, Stemcell Technologies, Fujifilm Holdings Corporation, Takara Bio Group, Lonza Group AG, Sartorius AG, Bio-Rad Laboratories, Becton Dickinson and Company, Bio-Techne Corporation, Miltenyi Biotec, Terumo BCT Inc., Corning Inc., Eppendorf AG, ViaCyte Inc., Merck KGaA, Danaher Corporation, Vericel Corporation, American Cryostem Corporation, Cellgenix GMBH, Aspen Neuroscience Inc., Magenta Therapeutics Inc, Pluristem Therapeutics Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., 3D Biomatrix Inc., Worthington Biochemical Corporation, Bico Group.

North America was the largest region in the stem cell manufacturing market in 2025. Europe was the second-largest region in the stem cell manufacturing market. The regions covered in the stem cell manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the stem cell manufacturing market by increasing the cost of imported bioreactors, media, reagents, and automated cell-processing equipment. Pharmaceutical companies and research laboratories in Asia-Pacific and Europe are most affected due to global sourcing of manufacturing inputs. These higher costs can slow scale-up of clinical-grade stem cell production. However, tariffs are driving domestic investment in cell-manufacturing infrastructure, improving long-term supply reliability.

The stem cell manufacturing market research report is one of a series of new reports that provides stem cell manufacturing market statistics, including stem cell manufacturing industry global market size, regional shares, competitors with a stem cell manufacturing market share, detailed stem cell manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell manufacturing industry. This stem cell manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell manufacturing involves the essential technologies that enable stem cell tissue culture, conducted in laboratories for therapeutic purposes, to be translated into clinical settings while ensuring control, reproducibility, automation, validation, and product safety.

The main products in stem cell manufacturing include consumables, instruments, and stem cell lines. Consumables are used for growing new cells in culture media, drug development, tissue culture, gene therapy, and toxicity testing. Applications include research, clinical use, and cell and tissue banking. End users include pharmaceutical and biotechnology companies, academic institutions, research laboratories and contract research organizations, hospitals and surgical centers, cell and tissue banks, and others.

The stem cell manufacturing market consists of sales of adult stem cells (ASCs), human embryonic stem cells (HESCs), induced pluripotent stem cells (iPSCs), and very small embryonic-like cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.